Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 8/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.52 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23309528 | 0.89 | PRSS12 (0.44) | ABL1MEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL23309615 | 0.86 | P2RX1 (0.58) | HTTNPC1RAB9ATSHRMAPT | |
| SCHEMBL23309730 | 0.86 | KMT2A (0.47) | MEN1KMT2AHTTSMN1; SMN2NPC1 | |
| SCHEMBL23309617 | 0.84 | NPC1 (0.54) | MEN1KMT2ASMN1; SMN2NPC1RAB9A | |
| SCHEMBL23309645 | 0.82 | ALDH1A1 (0.51) | MEN1KMT2AHTTSMN1; SMN2TRPV1 | |
| SCHEMBL23309562 | 0.82 | PNLIP (0.56) | MEN1KMT2AHTTSMN1; SMN2NPC1 | |
| SCHEMBL23309584 | 0.81 | NPC1 (0.57) | MEN1KMT2AHTTSMN1; SMN2NPC1 | |
| SCHEMBL23309621 | 0.80 | RAB9A (0.50) | MEN1KMT2AHTTSMN1; SMN2NPC1 | |
| SCHEMBL23309708 | 0.80 | RAB9A (0.52) | KMT2AHTTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL23309490 | 0.79 | GAA (0.51) | MEN1KMT2AHTTSMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210120817-A1 | PLANT DISEASE CONTROL AGENT | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2021-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210120817-A1 | PLANT DISEASE CONTROL AGENT | BROX, ALG1, CTRL | ABL1 3397/4885MEN1 1633/4885KMT2A 2360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.